ATE551345T1 - Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on - Google Patents
Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-onInfo
- Publication number
- ATE551345T1 ATE551345T1 AT05799991T AT05799991T ATE551345T1 AT E551345 T1 ATE551345 T1 AT E551345T1 AT 05799991 T AT05799991 T AT 05799991T AT 05799991 T AT05799991 T AT 05799991T AT E551345 T1 ATE551345 T1 AT E551345T1
- Authority
- AT
- Austria
- Prior art keywords
- methylüphenylü
- cdüindol
- azepinoä5
- methylamino
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61245904P | 2004-09-22 | 2004-09-22 | |
| US67929605P | 2005-05-09 | 2005-05-09 | |
| PCT/IB2005/002941 WO2006033007A2 (en) | 2004-09-22 | 2005-09-12 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551345T1 true ATE551345T1 (de) | 2012-04-15 |
Family
ID=35526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05799991T ATE551345T1 (de) | 2004-09-22 | 2005-09-12 | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7268126B2 (https=) |
| EP (1) | EP1799685B1 (https=) |
| JP (1) | JP2008513436A (https=) |
| KR (1) | KR100853601B1 (https=) |
| AR (1) | AR051296A1 (https=) |
| AT (1) | ATE551345T1 (https=) |
| AU (1) | AU2005286191B2 (https=) |
| BR (1) | BRPI0516766A (https=) |
| CA (1) | CA2581025C (https=) |
| ES (1) | ES2382950T3 (https=) |
| IL (1) | IL181463A (https=) |
| MX (1) | MX2007002461A (https=) |
| NO (1) | NO337938B1 (https=) |
| NZ (1) | NZ554659A (https=) |
| RU (1) | RU2355691C2 (https=) |
| TW (1) | TWI365188B (https=) |
| WO (1) | WO2006033007A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| KR20100102607A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| PH12012500928A1 (en) | 2009-11-09 | 2012-11-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| EP2534153B2 (en) | 2010-02-12 | 2024-05-22 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| KR102803917B1 (ko) | 2014-08-22 | 2025-05-07 | 파르마＆ 슈바이츠 게엠베하 | 루카파립의 고 용량 강도 정제 |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| US11161865B2 (en) | 2017-05-24 | 2021-11-02 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy |
| JP2021501771A (ja) * | 2017-11-03 | 2021-01-21 | サンド・アクチエンゲゼルシヤフト | 三環系ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤の結晶性塩 |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021156140A1 (en) | 2020-02-03 | 2021-08-12 | Sandoz Ag | Polymorph of rucaparib mesylate |
| EP4143182B1 (en) | 2020-04-28 | 2024-12-11 | Rhizen Pharmaceuticals AG | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
| WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| KR20260030809A (ko) | 2023-06-21 | 2026-03-06 | 테트라곤 바이오사이언시스 엘티디 | Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US649554A (en) * | 1899-04-08 | 1900-05-15 | Ferdinand Schwedtmann | Electric switch. |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| OA11749A (en) * | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
| MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
| SI1660095T1 (sl) * | 2003-07-25 | 2010-05-31 | Cancer Rec Tech Ltd | Triciklični parp inhibitorji |
-
2005
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en not_active Expired - Lifetime
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en not_active Ceased
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en not_active Ceased
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en not_active IP Right Cessation
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es not_active Expired - Lifetime
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko not_active Expired - Fee Related
- 2005-09-12 CA CA2581025A patent/CA2581025C/en not_active Expired - Lifetime
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh not_active IP Right Cessation
- 2005-09-21 US US11/233,835 patent/US7268126B2/en not_active Expired - Lifetime
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1799685B1 (en) | 2012-03-28 |
| NO20070920L (no) | 2007-03-15 |
| IL181463A0 (en) | 2007-07-04 |
| HK1116483A1 (en) | 2008-12-24 |
| NZ554659A (en) | 2010-08-27 |
| KR20070089121A (ko) | 2007-08-30 |
| IL181463A (en) | 2012-02-29 |
| ES2382950T3 (es) | 2012-06-14 |
| CA2581025A1 (en) | 2006-03-30 |
| EP1799685A2 (en) | 2007-06-27 |
| AR051296A1 (es) | 2007-01-03 |
| US7268126B2 (en) | 2007-09-11 |
| AU2005286191A1 (en) | 2006-03-30 |
| NO337938B1 (no) | 2016-07-11 |
| KR100853601B1 (ko) | 2008-08-22 |
| AU2005286191B2 (en) | 2011-11-17 |
| JP2008513436A (ja) | 2008-05-01 |
| CA2581025C (en) | 2011-06-07 |
| RU2007110026A (ru) | 2008-10-27 |
| TW200613305A (en) | 2006-05-01 |
| RU2355691C2 (ru) | 2009-05-20 |
| TWI365188B (en) | 2012-06-01 |
| MX2007002461A (es) | 2008-03-13 |
| BRPI0516766A (pt) | 2008-09-16 |
| WO2006033007A3 (en) | 2006-11-02 |
| US20060100198A1 (en) | 2006-05-11 |
| WO2006033007A2 (en) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551345T1 (de) | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on | |
| CY2020012I1 (el) | Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων | |
| DE602006020327D1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen | |
| ATE491700T1 (de) | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- | |
| DE602005020209D1 (de) | System zur Evaluierung von Herzstörungen | |
| FI20010460A0 (fi) | Autonrenkaan nasta | |
| DE602004006169D1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate | |
| ATE506362T1 (de) | 1-aza-bicycloä3.3.1ünonane | |
| UY28344A1 (es) | Nuevos compuestos | |
| IL185997A0 (en) | Substituted aryl 1.4-pyrazine derivatives background of the invention | |
| DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
| DE502006008804D1 (de) | Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen | |
| DE602005015369D1 (de) | Klipp zur gegenseitigen Befestigung von zwei Teilen | |
| EP1565448A4 (en) | PROCESS FOR THE PREPARATION OF 10H-DIBENZOçB, F] ç1,4] THIAZEPIN-11-ON | |
| ATE466840T1 (de) | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium | |
| ATE445604T1 (de) | Neue 2,6-diaminopyridin-3-on-derivate | |
| EP1883628A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF 3,5-DIETHYL-1,2-DIHYDRO-1-PHENYL-2-PROPYLPYRIDINE | |
| DE602004031556D1 (de) | Neue kristalline formen von 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-n-hydroxyethylimidazoä1,2-aüpyridin-6-carbonsäureamidmesylatsalz | |
| FR2888843B1 (fr) | Procede de preparation d'un diarylanthracene. | |
| ITMI20042402A1 (it) | Processo per la preparazione di n,n-dimetil-n'-feniluree | |
| DE602006018503D1 (de) | Verfahren zur herstellung von 1-benzyl-4-ä(5,6-dimethoxy-1indanon)-2-ylümethylpiperidin oder des hydrochlorids davon | |
| RU2002103738A (ru) | Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний | |
| DE602004009544D1 (de) | Neue 3,3-Dimethyl-5-Cyano-Benzoxepinderivate verwendbar zur Herstellung von 5-Formyl-Benzoxepinderivaten | |
| ITUD20050179A1 (it) | Apparecchiatura di condizionamento dell'aria | |
| ITUD20050176A1 (it) | Apparecchiatura di condizionamento dell' aria |